# ENCLOMIPHENE: Clinical Guide for Practices

> Enclomiphene is the active trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM) that blocks estrogen negative feedback at the hypothalamus and pituitary, stimulating endogenous LH, FSH, and testosterone production. It is widely compounded as a TRT alternative for men seeking testosterone optimization while preserving fertility.

**FDA compounding category:** Not FDA-approved as standalone compound; available through compounding. Racemic clomiphene (Clomid) is FDA-approved for female ovulation induction  
**Category:** Hormonal Support  
**Route of administration:** Oral capsule

## Mechanism of action

Enclomiphene competitively binds estrogen receptors (ER-alpha) at the hypothalamus and anterior pituitary, blocking the negative feedback of circulating estradiol [3]. This disinhibition increases GnRH pulse frequency, driving increased LH and FSH secretion [1]. The resulting gonadotropin elevation stimulates Leydig cell testosterone production and Sertoli cell spermatogenesis simultaneously, preserving fertility while raising serum testosterone [2].

## Evidence summary

Phase III clinical trials by Repros Therapeutics (Androxal program) demonstrated that enclomiphene 12.5-25mg daily significantly increased total testosterone, LH, and FSH in men with secondary hypogonadism while maintaining sperm counts [1]. The ZA-304 and ZA-305 trials showed non-inferiority to topical testosterone for testosterone elevation with superior preservation of spermatogenesis [4]. FDA approval was not obtained due to manufacturing issues, not efficacy concerns [1].

## Patient selection

Optimal for men with secondary hypogonadism (low T with low or inappropriately normal LH/FSH), particularly those desiring fertility preservation [2]. Best suited for total testosterone in the 200-400 ng/dL range seeking mild to moderate improvement [3]. Not appropriate for primary hypogonadism (elevated gonadotropins), severe symptomatic deficiency requiring rapid correction, or men who have failed prior SERM therapy [4].

## Clinical uses

- Endogenous testosterone optimization without exogenous hormone use
- Fertility preservation as an alternative to TRT
- Secondary hypogonadism treatment (hypothalamic-pituitary origin)
- Post-TRT recovery and HPTA axis restoration
- Testosterone support for men not ready to commit to TRT

## Protocols and dosing

Oral capsule, typically 12.5-25mg daily or every other day. Labs (total testosterone, free testosterone, LH, FSH, estradiol) checked at 4-6 weeks and dose adjusted based on response. Can be used continuously or cyclically.

Initiate at 12.5mg daily for 4-6 weeks and recheck total testosterone, free testosterone, LH, FSH, and estradiol [3]. If testosterone response is insufficient (target varies by patient goals), increase to 25mg daily [1]. Some clinicians use every-other-day dosing for maintenance [4]. Lipid panel and visual symptom screening should be performed at baseline and periodically. Discontinue immediately if visual disturbances occur [2].

## Side effects to monitor

- Visual disturbances (blurred vision, floaters, photophobia); rare but requires immediate discontinuation
- Mood changes and irritability (less common than with racemic clomiphene)
- Hot flashes and vasomotor symptoms (related to estrogen receptor blockade)
- Headache and nausea (typically mild and transient)
- Potential impact on lipid profiles (HDL reduction) with chronic use

## Clinical considerations

Not FDA-approved as standalone (compounded); distinguish from racemic clomiphene (Clomid),Vision changes (blurred vision, floaters) reported rarely; counsel patients to report immediately,Monitor estradiol levels (SERM action can alter E2 feedback dynamics),Lipid panel monitoring recommended (SERMs can affect lipid metabolism),Not appropriate for primary hypogonadism (testicular failure); requires functional testes and pituitary

## Practice economics

Enclomiphene is one of the highest-growth compounds in men's health, appealing to patients who want testosterone optimization without injections or fertility compromise [2]. Its oral route and favorable side-effect profile versus racemic clomiphene drive strong patient acceptance and retention [4]. It serves as an effective entry point for new patients, with potential conversion to broader protocols over time. Monthly prescription refills create reliable recurring revenue.

## Frequently asked questions

### What is the advantage of enclomiphene over racemic clomiphene (Clomid)?

Racemic clomiphene contains both trans (enclomiphene) and cis (zuclomiphene) isomers. Zuclomiphene is an estrogen receptor agonist with a long half-life (weeks) that can accumulate and cause estrogenic side effects (mood changes, visual disturbances). Pure enclomiphene provides the anti-estrogenic testosterone-boosting effect without zuclomiphene accumulation, resulting in fewer side effects and a cleaner pharmacologic profile.

### How does enclomiphene compare to TRT for testosterone optimization?

Enclomiphene stimulates endogenous testosterone production (preserving fertility and testicular function), while TRT provides exogenous testosterone (suppressing LH/FSH and spermatogenesis). Enclomiphene typically achieves testosterone levels of 500-800 ng/dL, which may be sufficient for many patients. TRT can achieve higher levels. Enclomiphene is preferred when fertility preservation is important or patients prefer to avoid injections.

### Which patients are ideal candidates for enclomiphene?

Ideal candidates have secondary hypogonadism (low testosterone with inappropriately normal/low LH), desire fertility preservation, prefer oral medication over injections, are younger men not ready for lifelong TRT, or have mild-to-moderate testosterone deficiency. Poor candidates include those with primary hypogonadism (elevated LH), severe deficiency requiring rapid correction, or those who have failed SERM therapy previously.

## Sources

- [Repros Therapeutics - Androxal (enclomiphene) Phase III trial results (ZA-304)](https://pubmed.ncbi.nlm.nih.gov/25044089/)
- [Kim et al. - Enclomiphene citrate raises testosterone while preserving sperm counts (2016)](https://pubmed.ncbi.nlm.nih.gov/27317420/)
- [Wiehle et al. - Enclomiphene citrate for secondary hypogonadism: Phase II data (2014)](https://pubmed.ncbi.nlm.nih.gov/24565573/)
- [Kaminetsky et al. - Oral enclomiphene vs topical testosterone in hypogonadal men (2013)](https://pubmed.ncbi.nlm.nih.gov/23260015/)

---

Canonical page: https://karpahealth.com/resources/peptides/enclomiphene/
Markdown version of the HTML page "enclomiphene" at that URL.
Machine-readable context: https://karpahealth.com/llms.txt · Pricing: https://karpahealth.com/pricing.md · Agents & API: https://karpahealth.com/agents.md